Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Monoclonal antibodies bevacizumab and cetuximab both improve overall survival (OS), progression free survival (PFS) and overall response rate (ORR) when combined with irinotecan-containing regimens. The optimal sequence of these monoclonal antibodies in combination with chemotherapy is controversial...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Grande, Roberta, Gemma, Donatello, Sperduti, Isabella, Gelibter, Alain, Giampaolo, Maria Anna, Trombetta, Giorgio, Nelli, Fabrizio, Gamucci, Teresa
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing AG 2013
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3647091/
https://ncbi.nlm.nih.gov/pubmed/23667824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-2-185
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi